Cargando…

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology

SIMPLE SUMMARY: Dipeptidyl peptidase (DPP)-4 inhibitor is widely used for type 2 diabetes. Although DPP-4/CD26 has been recognized as both a suppressor and inducer in tumor biology due to its various functions, how DPP-4 inhibitor affects cancer progression in diabetic patients is still unknown. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakita, Emi, Koya, Daisuke, Kanasaki, Keizo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124456/ https://www.ncbi.nlm.nih.gov/pubmed/34063285 http://dx.doi.org/10.3390/cancers13092191

Ejemplares similares

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
por: Kanasaki, Keizo, et al.
Publicado: (2019)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
por: Adhikari, Juthi, et al.
Publicado: (2023)

Cancer biology in diabetes
por: Sen, Shi, et al.
Publicado: (2014)

Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
por: Kawakita, Emi, et al.
Publicado: (2023)

Biology of Obesity: Lessons from Animal Models of Obesity
por: Kanasaki, Keizo, et al.
Publicado: (2011)

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
por: Li, Shaolan, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
por: Srivastava, Swayam Prakash, et al.
Publicado: (2013)

The Relevance of the Renin-Angiotensin System in the Development of Drugs to Combat Preeclampsia
por: Ueki, Norikazu, et al.
Publicado: (2015)

Autophagy as a Therapeutic Target in Diabetic Nephropathy
por: Tanaka, Yuki, et al.
Publicado: (2012)

Lipid mediators in diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Dietary Restriction Ameliorates Diabetic Nephropathy through Anti-Inflammatory Effects and Regulation of the Autophagy via Restoration of Sirt1 in Diabetic Wistar Fatty (fa/fa) Rats: A Model of Type 2 Diabetes
por: Kitada, Munehiro, et al.
Publicado: (2011)

Sirtuins and renal diseases: relationship with aging and diabetic nephropathy
por: Kitada, Munehiro, et al.
Publicado: (2012)

Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011)

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity
por: Kitada, Munehiro, et al.
Publicado: (2018)

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014)

Editorial: Receptor Biology and Cell Signaling in Diabetes
por: Srivastava, Swayam Prakash, et al.
Publicado: (2022)

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)

AMP-Activated Protein (AMPK) in Pathophysiology of Pregnancy Complications
por: Kumagai, Asako, et al.
Publicado: (2018)

CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma
por: Nishina, Sohji, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
por: Takagaki, Yuta, et al.
Publicado: (2019)

Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats
por: Ogura, Yoshio, et al.
Publicado: (2018)

Editorial: Receptor biology and cell signaling in diabetes: volume II
por: Srivastava, Swayam Prakash, et al.
Publicado: (2023)

Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium–glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin‐overloaded streptozotocin‐induced diabetic mice
por: Shimada, Keiji, et al.
Publicado: (2022)

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
por: Chitadze, Guranda, et al.
Publicado: (2021)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
por: Koyanagi, Yu, et al.
Publicado: (2023)

CD‐1(db/db) mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis
por: Mizunuma, Yuiko, et al.
Publicado: (2020)

Restoration of the Hypothalamic-pituitary-adrenal Response to Hypoglycemia in Type 2 Diabetes by Avoiding Chronic Hypoglycemia
por: Tsuda, Shin-ichi, et al.
Publicado: (2016)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness
por: Liang, Peir-In, et al.
Publicado: (2016)

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
por: Kaneko, Yutaro, et al.
Publicado: (2021)

The PKM2 activator TEPP‐46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF‐1α accumulation
por: Liu, Haijie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qcp465bv7rem63ujl5tbj8p2qs